This study aimed to examine the prevalence of glucose metabolism disorders (GMD)in the patients with coronary artery disease and the relationship between different GMDs and coronary artery disease (CAD).
Full Title of Study: “The Relationship Between Previously Unknown Glucose Metabolism Disorders and Coronary Artery Disease in Patients Suffering From Coronary Artery Disease”
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: June 2010
Context: There are more than 220 million people diagnosed with diabetes mellitus (DM) in the world. DM is a serious risk factor for coronary artery disease (CAD). This study aimed to examine the prevalence of glucose metabolism disorders (GMD) in te patients with coronary artery disease and the relationship between different GMDs and CAD.
Settings: 230 patients with coronary artery disease and without any known GMDs were included the study. Coronary angiography was used to diagnose CAD. Patients were administered the 75 g Oral Glucose Tolerance Test (OGTT).
- Other: ogtt for patients with coronary artery disease
- 75 g OGTT
Arms, Groups and Cohorts
- coronary artery disease
- patients with coronary artery disease
Clinical Trial Outcome Measures
- Frequency of unknown glucose metabolism disorders in patients with coronary artery disease
- Time Frame: 1 year
- Results: While GMDs were detected in 58.26% (n=134 patients) of CAD patients, 41.74% of them (n=96 patients) were found to have normal glucose metabolism.
- Fasting and 120 minute glucose levels have relation with vessels’ stenosis.
- Time Frame: 1 year
- Fasting glucose level was found to have a significant correlation with the total number of stenotic coronary vessels (p=0.0001) and the stenosis rate of all vessels . OGTT 120-minute glucose levels were found to have a significant correlation with the total number of stenotic coronary vessels and the stenosis rate of vessels with the exception of LAD.
Participating in This Clinical Trial
- Patients with coronary artery disease and who had no glucose metabolism disorders were included to study.
- Patients who had previous GMDs, malignancies, chronic liver and kidney diseases, rheumatologic disorders, and a BMI higher than 35 kg/m2 were excluded from the study.
Gender Eligibility: All
Minimum Age: 30 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Gulhane School of Medicine
- Provider of Information About this Clinical Study
- Gulhane School of Medicine, Dep. of Endocrinology and Metabolism
- Overall Official(s)
- Aydogan Aydogdu, MD, Study Director, Gulhane School of Medicine Ankara/Turkey
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.